Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy
2022 · Cell Metabolism · 527 citations
https://doi.org/10.1016/j.cmet.2022.09.021
Y
Yi‐Zhou Jiang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
402
Papers
9.5K
Citations
51
h-index
125
i10-index
Yi‐Zhou Jiang is an academic researcher from Nanjing Agricultural University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Cancer Genomics and Diagnostics & HER2/EGFR in Cancer Research. The author has an h-index of 51, co-authored 342 publications.
ORCID: 0000-0003-3699-2630Papers by this author
worksMetabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
2020 · Cell Metabolism · 467 citations
https://doi.org/10.1016/j.cmet.2020.10.012
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response
2021 · Journal of Hematology & Oncology · 437 citations
https://doi.org/10.1186/s13045-021-01103-4
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
2022 · Cell Research · 297 citations
https://doi.org/10.1038/s41422-022-00614-0
Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance
2020 · The Oncologist · 199 citations
https://doi.org/10.1634/theoncologist.2019-0982
Emerging therapies in cancer metabolism
2023 · Cell Metabolism · 197 citations
https://doi.org/10.1016/j.cmet.2023.07.006
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat